Stockscreener 앱 받기
16.11
0.72%
0.115
전일 마감가:
$16.00
열려 있는:
$16.03
하루 거래량:
39,822
Relative Volume:
1.73
시가총액:
$5.70B
수익:
$417.75M
순이익/손실:
$32.27M
주가수익비율:
165.28
EPS:
0.0975
순현금흐름:
-
1주 성능:
-1.68%
1개월 성능:
-5.15%
6개월 성능:
+0.09%
1년 성능:
+0.00%
1일 변동 폭
$15.90
$16.15
1주일 범위
$15.80
$16.72
52주 변동 폭
$13.61
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
TLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
16.11 | 5.70B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.75 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
524.05 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.55 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
548.98 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.44 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 개시 | Wedbush | Outperform |
| 2024-11-15 | 개시 | UBS | Buy |
Telix Pharmaceuticals Ltd Adr 주식(TLX)의 최신 뉴스
Revolutionary PSMA-PET Imaging Agent Gozellix Transforms Prostate Cancer Detection Across United States - Stock Titan
Leading Cancer Experts Reveal Future of Radiopharmaceuticals at Telix NYC Investor Day - Stock Titan
Telix Leaders Reveal Next-Gen Radiopharmaceutical Pipeline at Exclusive NYC Investor Day - Stock Titan
Radiopharmaceuticals Market Products and Applications Report 2025 | SPECT Radiopharmaceuticals Lead Diagnostic Market with 67% Share - GlobeNewswire Inc.
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - Stock Titan
Major Breakthrough: France Grants Approval for Advanced Prostate Cancer Detection Technology - Stock Titan
Telix Delivers Record $186M Q1 Revenue as New FDA-Approved Cancer Imaging Agent Bolsters Portfolio - Stock Titan
Breakthrough Brain Cancer Treatment Doubles Survival Time: Phase 2 Results Revealed - Stock Titan
Telix's Groundbreaking Prostate Cancer Imaging Tech Secures Nationwide Distribution Network - Stock Titan
Former ARTMS Tech Chief Joins Telix to Lead Next-Gen Radiopharmaceutical Innovation - Stock Titan
Major Board Addition: Ex-GSK and Sanofi Leader Joins Telix Pharmaceuticals - Stock Titan
Revolutionary Cancer Diagnostic Begins Human Trials: First Patient Receives Novel Sarcoma Imaging Agent - Stock Titan
FDA Green Lights Revolutionary Prostate Cancer Detection Tool: What Makes Gozellix a Game-Changer - StockTitan
Telix Pharmaceuticals Limited (ASX:TLX) Receives FDA Approval for Gozellix® - The Capital Club
Paladin Energy Ltd (ASX:PDN) Suspends Operations at Langer Heinrich Mine - The Capital Club
Major Breakthrough: First PSMA-PET Imaging Agent Approved in Brazil's $330M Market - StockTitan
Telix's Game-Changing Isotope Technology Revolutionizes Cancer Treatment Production - StockTitan
Can Telix's Cancer Therapies Transform Urology Treatment? Top Oncologists Weigh In - StockTitan
Could This New Kidney Cancer Imaging Tool Transform Diagnosis? FDA Fast-Tracks Review - StockTitan
Could This New Prostate Cancer Treatment Change Patient Outcomes? Miami Trial Now Recruiting - StockTitan
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Can Telix's Triple Product Launch in 2025 Justify Its Bold $1.2B Revenue Target? - StockTitan
Clinical Trial Success: Telix's Revolutionary Prostate Cancer Treatment Shows Promising Results - StockTitan
Major Breakthrough: Revolutionary Prostate Cancer Detection Tool Gets UK Green Light - StockTitan
Telix Pharmaceuticals acquires ImaginAb assets and technology - Investing.com
Telix Pharmaceuticals Acquires RLS USA in Major $230M Radiopharmacy Network Deal - Stock Titan
ImaginAb Sells Therapeutic Pipeline to Telix Pharmaceuticals, Focuses on CD8 ImmunoPET Development - Stock Titan
Telix Pharmaceuticals Hits Record $517M Revenue, Up 55% as Cancer Imaging Portfolio Expands - Stock Titan
Telix Pharmaceuticals Acquires ImaginAb's Cancer Drug Pipeline in $45M Strategic Deal - StockTitan
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Clayton Utz M&A partner Niro Ananda set to resign; KWM eyed - The Australian Financial Review
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
Key Investors Say Bet on These Stocks at Sohn Australia Conference - BNN Bloomberg
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Telix Pharmaceuticals Debuts on Nasdaq Global Select Market Under TLX Symbol - Stock Titan
Liverpool Partners, Adamantem seek new owner for Plena Healthcare - The Australian Financial Review
Guess which top 100 ASX stock is venturing off to the Nasdaq - The Motley Fool Australia
Telix Files Form 20-F Registration Statement for Nasdaq ADS - Yahoo Finance
Up 66% in FY24, will Telix Pharmaceuticals shares continue? - The Motley Fool Australia
TLX ASX: Telix pulls $300m Nasdaq IPO as investors demand deep discount - AFR
Radiopharma-focused Telix heats up IPO summer market with $200M offering - Fierce Biotech
Telix Pharmaceuticals to Acquire IsoTherapeutics Group - Contract Pharma
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Australia's Telix Pharmaceuticals jumps on potential US listing - Reuters.com
3 ASX shares for sustainable investment returns - Rask Media
Radiopharma production facility opens in Belgium - European Pharmaceutical Review
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Queen's University Leads Irish Trial of New Prostate Cancer Treatment - Imaging Technology News
Morningstar | Empowering Investor Success - Morningstar
Telix Pharmaceuticals Ltd Adr (TLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
자본화:
|
볼륨(24시간):